Antimicrobial resistance strains the wallet: Who pays when we hit the wall?

Antimicrobial resistance (AMR) poses a significant global health crisis, threatening to escalate healthcare costs and undermine the efficacy of modern medicine. As resistant pathogens render existing treatments ineffective, the economic implications are staggering, with projections estimating that AMR could cost the world $100 trillion by 2050. In Europe, antibiotic resistance incurs nearly €9 billion annually, while in the United States, it adds approximately $20 billion to direct healthcare expenses each year, excluding an estimated $35 billion in lost productivity. The burden of AMR is not uniformly distributed, disproportionately affecting vulnerable populations and straining healthcare systems. This letter emphasizes the urgent need for a multifaceted approach to combat AMR, including improved stewardship of antimicrobial agents, increased investment in research and development, and equitable access to effective treatment options. By recognizing the interconnectedness of human and environmental health, we can prioritize sustainable solutions to mitigate the financial and human costs associated with this looming health crisis.